• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱移行细胞癌。原发性肿瘤与后续复发之间的差异。

Transitional cell carcinoma of the bladder. Differences between primary tumour and following relapses.

作者信息

Pizza G, Viza D, Fini M, Cuzzocrea D, Menniti D, Corrado F

出版信息

Eur Urol. 1980;6(1):45-7. doi: 10.1159/000473286.

DOI:10.1159/000473286
PMID:7353578
Abstract

The presence of tumour-associated antigens in bladder carcinomas has been shown in leucocyte migration inhibition and lymphocyte stimulation using formalin-treated autologous tumour cells as antigen. The treatment of patients with an in vitro produced specific transfer factor enhances their reactivity in these tests. However, when tumour cells from relapses were substituted for those of the primary tumour, the reactivity previously observed was abolished. An antigenic modulation and/or a polymorphic expression of bladder tumour-associated antigens in secondary tumours is suggested and might be responsible for some immunological escapes.

摘要

利用经福尔马林处理的自体肿瘤细胞作为抗原,通过白细胞迁移抑制试验和淋巴细胞刺激试验已证实膀胱癌中存在肿瘤相关抗原。用体外产生的特异性转移因子治疗患者可增强他们在这些试验中的反应性。然而,当用复发肿瘤细胞替代原发肿瘤细胞时,先前观察到的反应性就消失了。这提示在继发性肿瘤中存在膀胱肿瘤相关抗原的抗原调制和/或多态性表达,这可能是某些免疫逃逸的原因。

相似文献

1
Transitional cell carcinoma of the bladder. Differences between primary tumour and following relapses.膀胱移行细胞癌。原发性肿瘤与后续复发之间的差异。
Eur Urol. 1980;6(1):45-7. doi: 10.1159/000473286.
2
Cell-mediated tumour immunity in patients with transitional cell carcinoma of the urinary bladder.膀胱移行细胞癌患者的细胞介导肿瘤免疫
Int Urol Nephrol. 1975;7(4):297-302. doi: 10.1007/BF02082119.
3
A new tumour marker tested in 98 patients with bladder carcinoma.一种新的肿瘤标志物在98例膀胱癌患者中进行了检测。
Ann R Coll Surg Engl. 1984 Nov;66(6):399-401.
4
Leukocyte migration inhibition assay in patients with bladder cancer.膀胱癌患者的白细胞迁移抑制试验
J Urol. 1979 Dec;122(6):746-9. doi: 10.1016/s0022-5347(17)56584-2.
5
CA-50 as tumour marker in transitional bladder carcinoma.CA-50作为移行性膀胱癌的肿瘤标志物。
Br J Urol. 1989 Jun;63(6):616-8. doi: 10.1111/j.1464-410x.1989.tb05256.x.
6
Immunologic reduction of bladder cancer recurrence rate.膀胱癌复发率的免疫性降低
J Urol. 1974 Feb;111(2):173-6. doi: 10.1016/s0022-5347(17)59919-x.
7
Expression of Leu-M1 antigens in carcinoma of the urinary bladder.膀胱癌细胞中Leu-M1抗原的表达
J Urol. 1986 May;135(5):1075-7. doi: 10.1016/s0022-5347(17)45978-7.
8
Expression of CD15 antigen in urinary bladder transitional cell carcinoma.CD15抗原在膀胱移行细胞癌中的表达
J Clin Pathol. 1990 Jul;43(7):541-3. doi: 10.1136/jcp.43.7.541.
9
[Immunological detection of an antigen associated with human bladder carcinoma cell lines].[与人类膀胱癌细胞系相关抗原的免疫学检测]
Nihon Hinyokika Gakkai Zasshi. 1982 Oct;73(10):1249-58. doi: 10.5980/jpnjurol1928.73.10_1249.
10
In vitro production of a transfer factor specific for transitional-cell carcinoma of the bladder.膀胱移行细胞癌特异性转移因子的体外制备。
Br J Cancer. 1976 Jun;33(6):606-11. doi: 10.1038/bjc.1976.98.